"The
Report Biomarkers in Drug Discovery - Integration in Early Stage
Promotes Use of Companion Diagnostics to Optimize Therapeutic
Outcomes provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
GBI
Research’s new report, “Biomarkers in Drug Discovery Integration
in Early Stage Promotes Use of Companion Diagnostics to Optimize
Therapeutic Outcomes” provides information and analysis on the
major trends and issues affecting biomarkers in the drug discovery
process. The report describes the history of biomarkers and their
role in fulfilling the unmet needs of the conventional drug discovery
process. The drivers and barriers for the biomarkers market, along
with the key issues faced in the application of biomarkers in the
drug discovery process, are highlighted. The report discusses some
important technologies being used in the discovery and validation of
biomarkers. The integration of different types of biomarkers in each
phase of the drug discovery and development process is also studied.
Additionally, the report talks about the strategic consolidations
that have taken place within the global biomarkers market. These
include mergers, acquisitions, and strategic partnerships among
companies involved in the manufacturing of biomarkers for drug
discovery and research. This report is built using data and
information sourced from proprietary databases, primary and secondary
research and in-house analysis by GBI Research’s team of industry
experts.
View Report At
:http://www.marketresearchreports.biz/analysis/149608
According
to Food and Drug Administration (FDA), a biological marker or
biomarker is defined as a characteristic that is objectively measured
and evaluated as an indicator of normal biologic processes,
pathogenic processes, or biological responses to a therapeutic
intervention. It can define a physiologic, pathologic or anatomic
characteristic or measurement that is thought to relate to some
aspect of normal or abnormal biologic function. Changes in biomarkers
following treatment may identify safety problems related to a drug
candidate or reveal a pharmacological activity that predicts an
eventual benefit from treatment. Biomarkers may reduce uncertainty in
drug development and evaluation by providing quantitative predictions
about drug performance.
Before
the application of biomarkers in drug discovery, the process had
various drawbacks such as high attrition rates, high costs and
erroneous predictions about drug safety and efficacy. The integration
of biomarkers has addressed these issues and made the drug discovery
process smoother and less costly. The conventional symptom-based drug
R&D process, also called the “one-size-fits-all” or
“blockbuster” model, is being replaced by personalized medicine
so that targeted treatment can be designed for individuals based on
their genetic codes
GBI
Research analysis indicates that the global biomarkers market has
seen substantial growth since 2004, due to improvements in technology
and the creation of favorable regulatory norms for the application of
biomarkers in drug discovery.
This
report focuses on the applications of biomarkers in drug development,
the market characterization, and promising biomarkers in various
therapy areas. Historic and future trends, strategic consolidations
and regulatory norms are the other areas discussed in the report.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/149608
Scope
- An overview of biomarkers in the drug discovery process along with their use, efficiency and limitations.
- Annualized market data from 2004 and forecast forward to 2018.
- Key market drivers and restraints for the biomarkers market.
- Important technologies being used in the discovery of biomarkers.
- Promising biomarkers that are expected to be used in the drug discovery process in the future.
- The integration of different types of biomarker in each phase of the drug discovery and development process
- Analysis of partnership and M&A deals from 2011 until August 2012.
Reasons to buy
- Develop better strategies for biomarkers research by understanding the market dynamics for the biomarker drug discovery industry.
- Develop market entry and market expansion strategies by identifying the key areas for high growth and opportunities.
- Understand the factors shaping the biomarkers drug discovery market.
- Reinforce the R&D pipeline by identifying the key biomarker tests that can provide more accurate and early diagnosis of diseases.
- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.
Table
of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Biomarkers in Drug Discovery -
Introduction 10
2.1 Introduction 10
3 Biomarkers in Drug Discovery -
Overview 11
3.1 History of Biomarkers 11
3.2 Biomarkers Cater to the Unmet
Needs in Drug Discovery 13
3.2.1 High Attrition Rates 14
3.2.2 High Drug Discovery Cost 15
3.2.3 Time Consuming 15
3.2.4 Safety and Efficacy 15
3.2.5 Invasiveness, Selectivity
and Sensitivity 15
3.3 Biomarker Discovery and the
Validation Process 16
3.3.1 Discovery 16
3.3.2 Development 17
3.3.3 Launch 17
4 Biomarkers in Drug Discovery -
Market Characterization 19
4.1 Market Size and Forecasts 19
4.2 Global Biomarkers Market –
Geographic Landscape 20
4.2.1 Introduction 20
4.2.2 North America 20
4.2.3 Europe 20
4.2.4 Asia 21
4.2.5 Row 21
4.3 Drivers and Barriers 21
4.3.1 Drivers for the Global
Biomarkers Market 22
4.3.2 Barriers for the Global
Biomarkers Market 24
5 Biomarkers in Drug Discovery -
Time Trends 25
5.1 Historic Trend 25
5.1.1 Predictions Based on
Biomarkers 25
5.1.2 Validation Versus
Qualification 25
5.1.3 Lack of Synergy between
Mechanism and Pattern 25
5.1.4 Regulatory Approval of
Biomarkers 26
5.1.5 Difference in Regulation of
Single Biomarkers and Panel of Biomarkers 26
5.1.6 Measures of Success 26
5.2 Future Trend – Growing
Demand for Personalized Medicine 27
5.2.1 Companion Diagnostics Market
27
5.2.2 Drivers and Barriers for
Companion Diagnostics Market 28
5.2.3 Regulations of Companion
Diagnostics – EU 28
5.2.4 Regulations of Companion
Diagnostics – US 29
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment